Roy Maute on Macrophage Checkpoint Inhibition: Pheast’s Vision for Advancing PHST001 in Solid Tumors

In this PharmaShots interview, Pheast Therapeutics’ CEO Roy Maute highlights the company’s strategy to harness macrophage checkpoint inhibition—and specifically the CD24 “don’t eat me” signal—to drive innate immune activation and overcome tumor immune evasion in solid tumors. Roy discusses how early clinical data findings support PHST001’s development as both a monotherapy and combination therapy, underscoring Pheast’s broader vision to establish macrophage-directed therapies as a differentiated and scalable immuno-oncology modality.

Read the full article here.